CPRX · As filed with the SEC
Catalyst Pharmaceuticals cash flow statement, by fiscal year
The statement as Catalyst Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities: | ||||||||
| Net income | 214,326,000 | 163,889,000 | 71,410,000 | 83,079,000 | 39,482,000 | 74,983,000 | 31,875,337 | (34,003,514) |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||
| Depreciation | 375,000 | 397,000 | 316,000 | 141,000 | 192,000 | 92,065 | 54,327 | 37,978 |
| Stock-based compensation | 24,778,000 | 22,251,000 | 14,250,000 | 7,907,000 | 6,073,000 | 6,260,923 | 3,824,815 | 3,550,644 |
| Amortization of intangible assets | 37,498,000 | 37,377,000 | 32,565,000 | 1,098,000 | — | — | — | — |
| Deferred taxes | (6,849,000) | (9,388,000) | (17,818,000) | 4,937,000 | 9,316,000 | (32,971,264) | — | — |
| Change in accrued interest and accretion of discount on investments | — | — | — | 17,000 | (5,000) | (12,191) | (290,805) | — |
| Accretion of discount | (350,000) | (835,000) | 1,320,000 | — | — | — | — | — |
| Reduction in the carrying amount of right-of-use asset | 295,000 | 278,000 | 262,000 | 247,000 | 292,000 | 793,252 | 243,399 | — |
| Realized loss on sale of available-for-sale securities | — | 0 | — | 762,000 | — | — | — | — |
| Acquired research and development inventory expensed from asset acquisition | — | — | — | 4,130,000 | — | — | — | — |
| Acquired research and development inventory expensed from asset acquisition | — | 0 | — | — | — | — | — | — |
| Acquired inventory samples expensed from asset acquisition | 0 | 0 | 130,000 | — | — | — | — | — |
| Acquired in-process research and development | 0 | 0 | 81,513,000 | — | — | — | — | — |
| Change in fair value of equity securities | (972,000) | (5,075,000) | (3,024,000) | — | — | — | — | — |
| Inventory reserve and write-offs | 464,000 | — | — | — | — | — | — | — |
| (Increase) decrease in: | ||||||||
| Accounts receivable, net | (61,001,000) | (11,962,000) | (43,075,000) | (3,820,000) | (632,000) | 4,549,571 | (10,536,997) | — |
| Inventory, net | (18,089,000) | (3,897,000) | (4,739,000) | 1,065,000 | (3,219,000) | (2,693,808) | (1,900,780) | (56,012) |
| Prepaid expenses and other current assets | (177,000) | (8,504,000) | (5,792,000) | (807,000) | 3,977,000 | (3,976,697) | (2,701,293) | (476,037) |
| Increase (decrease) in: | ||||||||
| Accounts payable | (5,391,000) | 1,798,000 | 10,820,000 | 1,207,000 | (1,488,000) | 138,573 | 1,780,080 | 391,792 |
| Accrued expenses and other liabilities | 24,164,000 | 53,848,000 | 5,800,000 | 16,391,000 | 5,520,000 | (1,209,280) | 12,540,197 | 4,850,743 |
| Operating lease liability | — | — | — | — | — | (919,280) | (276,807) | — |
| Operating lease liability | (401,000) | (369,000) | (338,000) | (307,000) | 864,000 | — | — | — |
| Net cash provided by (used in) operating activities | 208,670,000 | 239,808,000 | 143,600,000 | 116,047,000 | 60,372,000 | 45,034,864 | 34,611,473 | (25,704,406) |
| Investing Activities: | ||||||||
| Purchases of property and equipment | (58,000) | (556,000) | (231,000) | (29,000) | (1,021,000) | (11,398) | (19,369) | (92,018) |
| Purchases of investments | — | — | — | — | (10,000,000) | (10,000,000) | (34,725,401) | (36,802,418) |
| Proceeds from maturities and sales of investments | — | — | — | — | 0 | 5,000,000 | 71,969,365 | 21,368,425 |
| Proceeds from sale of available-for-sale securities | — | 0 | — | 19,238,000 | — | — | — | — |
| Payment in connection with license agreement | — | — | — | (10,000,000) | — | — | — | — |
| Payments in connection with asset acquisitions | 0 | 0 | (198,293,000) | — | — | — | — | — |
| Acquisition of in-process research and development | 0 | 0 | (81,513,000) | — | — | — | — | — |
| Purchase of equity securities | 0 | 0 | (13,465,000) | — | — | — | — | — |
| Net cash provided by (used in) investing activities | (58,000) | (556,000) | (293,502,000) | 9,209,000 | (11,021,000) | (5,011,398) | 37,224,595 | (15,526,011) |
| Financing Activities: | ||||||||
| Payment of employee withholding tax related to stock-based compensation | (1,773,000) | (668,000) | (982,000) | (230,000) | (153,000) | (56,197) | 0 | (4,448) |
| Proceeds from exercise of stock options | 14,669,000 | 13,515,000 | 2,792,000 | 9,569,000 | 4,099,000 | 758,130 | 1,116,242 | 297,563 |
| Repurchase of common stock | (25,300,000) | 0 | — | (6,907,000) | (12,089,000) | — | — | — |
| Payment of liabilities arising from asset acquisition | (4,590,000) | (12,886,000) | (12,667,000) | (738,000) | — | — | — | — |
| Proceeds from issuance of common stock | 0 | 141,000,000 | — | — | — | — | — | — |
| Payment of fees in connection with issuance of common stock | 0 | (296,000) | — | — | — | — | — | — |
| Net cash provided by (used in) financing activities | (16,994,000) | 140,665,000 | (10,857,000) | 1,694,000 | (8,143,000) | 701,933 | 1,116,242 | 293,115 |
| Net increase (decrease) in cash and cash equivalents | — | — | — | — | — | — | — | (40,937,302) |
| Net increase (decrease) in cash and cash equivalents | 191,618,000 | 379,917,000 | (160,759,000) | 126,950,000 | 41,208,000 | 40,725,399 | 72,952,310 | — |
| Cash and cash equivalents – beginning of period | — | — | — | 171,445,000 | 130,237,000 | 89,511,710 | 16,559,400 | 57,496,702 |
| Cash and cash equivalents – end of period | — | — | — | — | 171,445,000 | 130,237,109 | 89,511,710 | 16,559,400 |
| Cash and cash equivalents – beginning of period | 517,553,000 | 137,636,000 | 298,395,000 | 171,445,000 | 130,237,000 | — | — | — |
| Cash and cash equivalents – end of period | 709,171,000 | 517,553,000 | 137,636,000 | 298,395,000 | — | — | — | — |
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for income taxes | 71,986,000 | 68,451,000 | 50,458,000 | 7,667,000 | 3,000,000 | 2,785,497 | — | — |
| Cash paid for interest | 466,000 | 1,395,000 | 705,000 | — | — | — | — | — |
| Non-cash investing and financing activities: | ||||||||
| Unrealized gain (loss) on available-for-sale securities | — | — | — | — | — | 21,827 | 29,753 | (20,248) |
| Operating lease liabilities arising from obtaining right-of-use assets | — | — | — | — | 3,309,000 | — | — | — |
| Liabilities arising from asset acquisition | 0 | 0 | 1,915,000 | 27,699,000 | — | — | — | — |
| Accrued milestone payment classified as license and acquired intangibles, net | 12,500,000 | — | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.